Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical, Inc. (Nasdaq: ICUI) is a medical technology company that publicly reports on its performance and activities through regular news releases and investor communications. The company describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings, and it is headquartered in San Clemente, California.
The ICUI news feed on Stock Titan aggregates company announcements that cover a range of topics important to investors and industry observers. These include quarterly earnings results, updates to fiscal year guidance, and details on product line revenues across Consumables, Infusion Systems and Vital Care. ICU Medical’s earnings releases also discuss items such as gross profit, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted diluted earnings per share, and commentary from management on recent performance.
In addition to financial results, ICU Medical issues news about corporate and strategic developments. Recent disclosures include the completion of Otsuka ICU Medical LLC, a joint venture with Otsuka Pharmaceutical Factory, Inc. focused on IV solutions manufacturing and innovation in North America. The company also announces its participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and events hosted by Piper Sandler, Wells Fargo and Morgan Stanley.
Through these updates, readers can follow how ICU Medical communicates its business progress, financial outlook and strategic initiatives. The ICUI news page on Stock Titan provides a centralized view of press releases related to earnings, guidance, joint ventures, conference appearances and other material events referenced in the company’s SEC filings. Investors and researchers can use this stream of information to monitor developments in ICU Medical’s infusion systems, consumables, vital care product lines and broader corporate activities over time.
ICU Medical (Nasdaq:ICUI) announced its third quarter 2021 earnings release will occur on November 3, 2021, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible via phone at (877) 407-3982 or through a webcast on the company's website. ICU Medical specializes in infusion therapy and critical care products, including IV smart pumps and safety software. The webcast will also be available for replay.
ICU Medical has announced its commitment to acquire Smiths Medical, expanding its infusion therapy capabilities with estimated combined revenues of $2.5 billion. The deal includes 2.5 million newly issued shares valued at $500 million and $1.85 billion in cash, alongside certain liabilities. Smiths will hold a 10% stake in ICU Medical post-transaction, with a board seat contingent on stock ownership. The acquisition is subject to regulatory approvals and is anticipated to close in H1 2022, strengthening ICU Medical's market position and enhancing customer service.
ICU Medical has announced a voluntary recall of one lot (2,112 units) of Aminosyn II, 15% due to visible particulate matter. This recall, effective nationwide, was initiated after fibers and proteinaceous material were detected in retain samples during routine inspections. The recalled product could pose health risks, including inflammation or severe blood clots. To date, no adverse events have been reported. The product is intended for nutritional support in patients unable to tolerate oral intake. Customers are advised to cease use and return the product.
ICU Medical reported second quarter 2021 revenue of $321.7 million, up from $303.4 million a year earlier. Gross profit rose to $123.5 million, with a gross margin of 38%, compared to 35% in Q2 2020. Net income was $28.4 million or $1.31 per diluted share, increasing from $18.9 million or $0.88 per share in the prior year. The company updated its 2021 guidance, adjusting expected adjusted EBITDA to $250 million to $260 million and adjusted diluted EPS to $6.80 to $7.20.
ICU Medical (Nasdaq:ICUI) will release its second quarter 2021 financial results on August 4, 2021, at approximately 4:00 p.m. ET. A conference call will follow at 4:30 p.m. ET, accessible at (866) 248-8441 or via webcast on the company's website. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications, with a comprehensive portfolio including IV smart pumps and cardiac monitoring systems. For more information, visit www.icumed.com.
ICU Medical, Inc. (Nasdaq:ICUI) reported its first-quarter 2021 financial results, revealing revenues of $318.0 million, down from $328.6 million in Q1 2020. The GAAP gross profit for the quarter fell to $112.7 million, yielding a 35% gross margin, compared to 37% the previous year. Despite this decline, GAAP net income increased to $23.7 million or $1.09 per diluted share, up from $16.8 million or $0.78 per diluted share in Q1 2020. Adjusted diluted EPS decreased to $1.62 from $1.81.
ICU Medical, Inc. (Nasdaq:ICUI) announced its first quarter 2021 earnings release scheduled for May 6, 2021, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call can be accessed via phone or streamed through the Company’s website. ICU Medical specializes in innovative medical products for infusion therapy and critical care, including IV smart pumps and cardiac monitoring systems. For more information, visit www.icumed.com.
ICU Medical, Inc. (Nasdaq:ICUI) will engage in a virtual fireside chat during the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at 7:45 a.m. PT (10:45 a.m. ET). The chat will be streamed live on the company's website, and a replay will also be available. ICU Medical specializes in innovative medical products for infusion therapy and critical care, including IV smart pumps and safety software. The event aims to provide insights into the company’s advancements and market position.
ICU Medical (Nasdaq:ICUI) announced its fourth quarter 2020 financial results, reporting revenues of $320.5 million, up from $315.5 million year-over-year. The GAAP gross profit rose to $119.9 million with a gross margin of 37%. Net income reached $26.1 million or $1.21 per diluted share, compared to $20.6 million or $0.96 per share in Q4 2019. Adjusted diluted EPS decreased to $1.77 from $1.94. For 2021, the company projects adjusted EBITDA between $245 million and $265 million, and adjusted diluted EPS of $6.50 to $7.20.
ICU Medical, Inc. (Nasdaq:ICUI) announced its participation at the Raymond James 42nd Annual Institutional Investors Conference, taking place virtually from March 1-3, 2021. The company’s management will deliver a presentation on March 1, 2021, at 1:40 p.m. PST (4:40 p.m. EST). Investors can access the live webcast on the company's website under the Investors tab and the Event Calendar tab, with a replay available afterward. ICU Medical specializes in innovative medical products for infusion therapy and critical care applications.